Cardio Diagnostics Holdings, Inc. (CDIO): R&D Expense
$641.2K
Year ended 2025-12-31
+151.2%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $641.2K | +181.3% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $228.0K | +57.0% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $145.2K | +258.9% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $40.4K | +28.5% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $31.5K | n/a | 2023-03-31, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | 2025-12-31 | $641.2K | +181.3% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $245.07M | +49.8% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $10.08M | -30.0% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $15.90M | +61.6% |
| Biomerica Inc (BMRA) | 2026-05-31 | $788.0K | -23.0% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $201.3K | -55.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
Compare CDIO, CLDX, VNRX, IMDX side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗